Search
forLearn
5 / 801 resultslearn Beta glucan
learn ascorbic acid
learn oligopeptide-71
learn Glycyrrhizic Acid 2K
Research
5 / 1000+ resultsresearch SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients
Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.
research Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19
Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
research 219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid
Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
research Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
research Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.
Community Join
5 / 1000+ resultscommunity Are there a lot of young folks here on fin?
Young people who have used finasteride and minoxidil to treat hair loss, with generally positive results reported by those taking the treatments.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.